Literature DB >> 6322391

Primary cytomegalovirus infection following cardiac transplantation in a murine model.

R H Rubin, E J Wilson, L V Barrett, D N Medearis.   

Abstract

A murine cytomegalovirus (CMV) model was utilized to determine the source of primary CMV infection in cardiac transplantation. Hearts were taken from actively or latently infected BALB/C mice and then transplanted as primary, heterotopic isografts into CMV-negative BALB/C recipients. The transplantation of hearts from acutely infected donors into nonimmunosuppressed recipients resulted in asymptomatic primary infection as manifested by detectable virus in both donor and recipient hearts, liver, spleen, and salivary glands and by the development of anti-CMV antibody. When hearts from latently infected animals were transplanted into nonimmunosuppressed recipients, a transient primary infection occurred that was manifested by detectable virus in the spleen and salivary glands and the appearance of anti-CMV antibody. When recipient animals were immunosuppressed with cortisone acetate (125 mg/kg/day i.p.) and rabbit antimouse thymocyte globulin (0.2 ml i.p. twice weekly), after transplantation of hearts from acutely and latently infected mice, lethal primary CMV infection developed. High titers of virus were recovered in all organs tested in these animals, including both the donor and recipient hearts. We conclude that the heart is infected during the course of primary murine CMV infection, and that hearts from latently infected animals are a source of serious primary infection in immunosuppressed recipients. This experimental system should be a useful model relevant to human cardiac transplantation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6322391     DOI: 10.1097/00007890-198403000-00018

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  9-(1-3-Dihydroxy-2-propoxymethyl)guanine prevents death but not immunity in murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice.

Authors:  E J Wilson; D N Medearis; L A Hansen; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 2.  Animal cytomegaloviruses.

Authors:  J Staczek
Journal:  Microbiol Rev       Date:  1990-09

3.  Myopericarditis and enhanced dystrophic cardiac calcification in murine cytomegalovirus infection.

Authors:  D L Gang; L V Barrett; E J Wilson; R H Rubin; D N Medearis
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

4.  Lack of association between cytomegalovirus infection of heart and rejection-like inflammation.

Authors:  P G Stovin; T G Wreghitt; T A English; J Wallwork
Journal:  J Clin Pathol       Date:  1989-01       Impact factor: 3.411

5.  Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice.

Authors:  R H Rubin; P Lynch; M S Pasternack; D Schoenfeld; D N Medearis
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

6.  Lungs are a major organ site of cytomegalovirus latency and recurrence.

Authors:  M Balthesen; M Messerle; M J Reddehase
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

7.  Shedding light on the elusive role of endothelial cells in cytomegalovirus dissemination.

Authors:  Torsten Sacher; Joachim Andrassy; Aivars Kalnins; Lars Dölken; Stefan Jordan; Jürgen Podlech; Zsolt Ruzsics; Karl-Walter Jauch; Matthias J Reddehase; Ulrich H Koszinowski
Journal:  PLoS Pathog       Date:  2011-11-17       Impact factor: 6.823

8.  The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease.

Authors:  M J Reddehase; M Balthesen; M Rapp; S Jonjić; I Pavić; U H Koszinowski
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

9.  Reconstitution of CD8 T Cells Protective against Cytomegalovirus in a Mouse Model of Hematopoietic Cell Transplantation: Dynamics and Inessentiality of Epitope Immunodominance.

Authors:  Rafaela Holtappels; Niels A W Lemmermann; Jürgen Podlech; Stefan Ebert; Matthias J Reddehase
Journal:  Front Immunol       Date:  2016-06-14       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.